Analysts Offer Predictions for AARD FY2027 Earnings

Aardvark Therapeutics, Inc. (NASDAQ:AARD) – Stock analysts at HC Wainwright issued their FY2027 earnings estimates for shares of Aardvark Therapeutics in a research report issued to clients and investors on Monday, July 20th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($1.98) for the year. HC Wainwright has a “Neutral” rating and a $6.00 price target on the stock. The consensus estimate for Aardvark Therapeutics’ current full-year earnings is ($3.46) per share.

Aardvark Therapeutics (NASDAQ:AARD) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.99) EPS for the quarter.

Several other research analysts have also recently commented on the company. Weiss Ratings upgraded Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 2nd. BTIG Research downgraded Aardvark Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Morgan Stanley reaffirmed an “underweight” rating and issued a $3.00 target price (down from $7.00) on shares of Aardvark Therapeutics in a research report on Friday, May 15th. Finally, B. Riley Financial reduced their target price on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $16.30.

Aardvark Therapeutics Price Performance

Shares of Aardvark Therapeutics stock opened at $6.08 on Tuesday. The business has a 50-day moving average of $4.82 and a 200-day moving average of $7.42. The company has a market capitalization of $133.03 million, a PE ratio of -1.89 and a beta of 3.93. Aardvark Therapeutics has a 1-year low of $3.35 and a 1-year high of $17.94.

Hedge Funds Weigh In On Aardvark Therapeutics

Several large investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Aardvark Therapeutics in the second quarter worth about $42,000. China Universal Asset Management Co. Ltd. bought a new stake in Aardvark Therapeutics in the fourth quarter valued at about $47,000. Persistent Asset Partners Ltd acquired a new stake in Aardvark Therapeutics during the fourth quarter valued at approximately $56,000. New York State Common Retirement Fund acquired a new stake in Aardvark Therapeutics during the second quarter valued at approximately $99,000. Finally, MetLife Investment Management LLC bought a new position in Aardvark Therapeutics during the 4th quarter worth approximately $102,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.